Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease

• Published in: Neurobiology of disease Vol. 183; p. 106175
• Main Authors: Snellman, Anniina, Ekblad, Laura L., Ashton, Nicholas J., Karikari, Thomas K., Lantero-Rodriguez, Juan, Pietilä, Elina, Koivumäki, Mikko, Helin, Semi, Karrasch, Mira, Zetterberg, Henrik, Blennow, Kaj, Rinne, Juha O.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2023; Elsevier
• Subjects: Aged; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - genetics; Alzheimer's disease; Amyloid beta-Peptides; APOE; Apolipoprotein E; Apolipoprotein E3; Apolipoprotein E4 - genetics; beta-amyloid; Biomarker; Biomarkers; Blood biomarkers; Cognitive Dysfunction - diagnostic imaging; Cognitive Dysfunction - genetics; GFAP; Glial Fibrillary Acidic Protein; Humans; Neurosciences; Neurovetenskaper; P-tau181; P-tau231; Preclinical; tau Proteins; Biomarker; AD; CNS; P-tau181; Simoa; p-tau; GFAP; Blood biomarkers; P-tau231; beta-amyloid; APCC; Aβ; VOI; Apolipoprotein E; MMSE; CSF; SUVR; Preclinical; APOE; Alzheimer's disease; PET

Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels and their association with regional β-amyloid (Aβ) pathology and cognitive performance head-to-head in clinically...